These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12771512)

  • 1. Transcription factors: new targets for antiallergic therapy.
    Quarcoo D; Hamelmann E
    Pathobiology; 2002-2003; 70(5):293-6. PubMed ID: 12771512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRE-palindrome oligonucleotide as a transcription factor decoy and an inhibitor of tumor growth.
    Cho-Chung YS
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):167-70. PubMed ID: 9593058
    [No Abstract]   [Full Text] [Related]  

  • 3. Antisense approaches to cancer gene therapy.
    Mercola D; Cohen JS
    Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotide derivatives as gene-targeted drugs.
    Knorre DG; Vlassov VV
    Biomed Sci; 1990 Apr; 1(4):334-43. PubMed ID: 1723003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional regulation of the human proenkephalin gene by conformational switching: implications for decoy design.
    Spiro C; McMurray CT
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):159-65. PubMed ID: 9593057
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic oligonucleotides: the road not taken.
    Stein CA; Goel S
    Clin Cancer Res; 2011 Oct; 17(20):6369-72. PubMed ID: 21862637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides.
    Morishita R; Tomita N; Kaneda Y; Ogihara T
    Curr Opin Pharmacol; 2004 Apr; 4(2):139-46. PubMed ID: 15063357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A novel paradigm and new targets in cancer therapy].
    Novik AA; Kamilova TA; Tsygan VN
    Vopr Onkol; 2003; 49(6):695-704. PubMed ID: 14976912
    [No Abstract]   [Full Text] [Related]  

  • 11. Searching for the ideal partner.
    Eckstein F
    Nat Biotechnol; 1998 Jan; 16(1):24. PubMed ID: 9447587
    [No Abstract]   [Full Text] [Related]  

  • 12. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Applications of antisense oligonucleotides in oncology].
    Pierga JY; Cammilleri S; Benyahia B; Magdelénat H
    Bull Cancer; 1994 Dec; 81(12):1023-42. PubMed ID: 7742591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERalpha transcriptional activity and MCF-7 proliferation.
    Cavarretta IT; Mukopadhyay R; Lonard DM; Cowsert LM; Bennett CF; O'Malley BW; Smith CL
    Mol Endocrinol; 2002 Feb; 16(2):253-70. PubMed ID: 11818499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
    Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
    Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear transcription factors: potential targets for new modes of intervention in skin disease.
    McKay IA; Winyard P; Leigh IM; Bustin SA
    Br J Dermatol; 1994 Nov; 131(5):591-7. PubMed ID: 7999587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional involvement of Pax-1 in somite development: somite dysmorphogenesis in chick embryos treated with Pax-1 paired-box antisense oligodeoxynucleotide.
    Smith CA; Tuan RS
    Teratology; 1995 Dec; 52(6):333-45. PubMed ID: 8711620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
    Nesterova MV; Cho-Chung YS
    Clin Cancer Res; 2004 Jul; 10(13):4568-77. PubMed ID: 15240549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense and RNA interference approaches to target validation in pain research.
    Kurreck J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.